for people ages 65 years and up (full criteria)
at Sacramento, California
study started
estimated completion
Principal Investigator
by Ling-Xin Chen, MD



Previous studies have shown that elderly patients experience higher trough levels of tacrolimus and are more sensitive to the effects of medications, they experience higher occurrence and severity of such medication related toxicities. Therefore, the investigators hypothesize that by transitioning patients from tacrolimus immediate release to Envarsus ®, the peak-dose effect will be eliminated or attenuated, leading to a significant decrease in neurocognitive toxicities in the older patient population.

Official Title

A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients


The investigators will conduct a single-center, prospective, open-label, randomized study to evaluate the difference in neurocognitive side effects between Envarsus and immediate release tacrolimus. Eligible patients will be enrolled within 8 weeks post-transplantation. They will be administered a baseline panel of neurocognitive tests. They will then be randomized to either continue on immediate release tacrolimus or Envarsus. 6 weeks after randomization, the neurocognitive tests will be repeated.


Kidney Transplant; Complications Toxicity Drug Toxicity Neurotoxicity Elderly Calcineurin inhibitors Tacrolimus Neurotoxicity Syndromes Drug-Related Side Effects and Adverse Reactions Envarsus IR Tacrolimus Immediate Release Tacrolimus


You can join if…

Open to people ages 65 years and up

  1. Recipient of a kidney transplant
  2. Age 65 or greater at the time of transplant
  3. Kidney graft is functional (not dialysis dependent) by 4 weeks post-transplant
  4. Have IR tacrolimus as maintenance therapy
  5. Have BMI < 35 at time of transplant
  6. Achieve therapeutic tacrolimus level within 4 weeks post-transplant

You CAN'T join if...

  1. Recipient of a simultaneous non-kidney transplant (pancreas)
  2. Had an episode of rejection before study enrollment
  3. Had a TIA/CVA after transplantation and before study enrollment
  4. Had a neurologic injury after transplantation and before study enrollment
  5. Blindness
  6. Have an mTOR inhibitor as maintenance therapy
  7. Nonadherence, as determined by a trough level less than 7 ng/mL after achieving therapeutic level with no other rationale for sub-therapeutic levels.
  8. Adults unable to consent
  9. Pregnant women
  10. . Prisoners


  • UC Davis accepting new patients
    Sacramento California 95817 United States

Lead Scientist at UC Davis

  • Ling-Xin Chen, MD
    Assistant Professor, Internal Medicine. Authored (or co-authored) 10 research publications.


accepting new patients
Start Date
Completion Date
University of California, Davis
Sign up for this study
Phase 4
Study Type
Last Updated